Lanreotide extended-release aqueous-gel formulation, injected by patient, partner or healthcare provider in patients with acromegaly in the United States: 1-year data from the SODA registry

Pituitary

Volumn 17, Issue 1, 2014, Pages 13-21

  Salvatori, Roberto ^a   Woodmansee, Whitney W ^b   Molitch, Mark ^c   Gordon, Murray B ^d   Lomax, Kathleen G ^e  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d ALLEGHENY GENERAL HOSPITAL   (United States)

^e IPSEN   (France)

Author keywords

Acromegaly; Extended release; Lanreotide depot; Observational study

Indexed keywords

ACROMEGALY; ADOLESCENT; ADULT; AGED; DELAYED-ACTION PREPARATIONS; FEMALE; HEALTH PERSONNEL; HUMANS; INJECTIONS, SUBCUTANEOUS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; SOMATOSTATIN;

EID: 84895076332     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-012-0460-2     Document Type: Article

References (19)

1. Katznelson L, Atkinson JL, Cook DM, Ezzat SZ, Hamrahian AH, Miller KK (2011) American Association of clinical Endocrinologists: American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly-2011 update. Endocr Pract 17(Suppl 4):1-44
2. Rosario PW (2011) Frequency of acromegaly in adults with diabetes or glucose intolerance and estimated prevalence in the general population. Pituitary 14(3):217-221
3. Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A (2006) High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 91(12):4769-4775
4. Schneider HJ, Sievers C, Saller B, Wittchen HU, Stalla GK (2008) High prevalence of biochemical acromegaly in primary care patients with elevated IGF-1 levels. Clin Endocrinol (Oxf) 69(3):432-435
5. Dekkers OM, Biermasz NR, Pereira AM, Romijn JA, Vandenbroucke JP (2008) Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab 93(1):61-67
6. Melmed S (2006) Medical progress: acromegaly. N Engl J Med 355(24):2558-2573
7. Webb SM (2006) Quality of life in acromegaly. Neuroendocrinology 83(3-4):224-229
8. Cook DM, Ezzat S, Katznelson L, Kleinberg DL, Laws ER Jr, Nippoldt TB, Swearingen B, Vance ML (2004) American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly. Endocr Pract 10:213-225
9. Ben-Shlomo A, Sheppard MC, Stephens JM, Pulgar S, Melmed S (2011) Clinical, quality of life, and economic value of acromegaly disease control. Pituitary 14(3):284-294
10. Giustina A, Bronstein MD, Casanueva FF, Chanson P, Ghigo E, Ho KK, Klibanski A, Lamberts S, Trainer P, Melmed S (2011) Current management practices for acromegaly: an international survey. Pituitary 14(2):125-133
11. ® in the treatment of acromegaly. Expert Rev Endocrinol Metab 2(3):433-441
12. Somatuline Depot prescribing information (2012) Ipsen biopharmaceuticals. Inc. Basking Ridge, NJ
13. Salvatori R, Nachtigall LB, Cook DM, Bonert V, Molitch ME, Blethen S, Chang S (2010) SALSA study group: effectiveness of self or partner administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naïve patients with acromegaly. Pituitary 13(2):115-122
14. Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D (2005) Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 90(8):4465-4473
15. Zwibel H, Pardo G, Smith S, Denney D, Oleen-Burkey M (2011) A multicenter study of the predictors of adherence to self-injected glatiramer acetate for treatment of relapsing-remitting multiple sclerosis. J Neurol 258(3):402-411
16. Cameron ST, Glasier A, Johnstone A (2012) Pilot study of home self-administration of subcutaneous depo-medroxyprogesterone acetate for contraception. Contraception 85(5):458-464
17. Bygum A, Andersen KE, Mikkelsen CS (2009) Self-administration of intravenous C1-inhibitor therapy for hereditary angioedema and associated quality of life benefits. Eur J Dermatol 19(2):147-151
18. Colwell CW Jr, Pulido P, Hardwick ME, Morris BA (2005) Patient compliance with outpatient prophylaxis: an observational study. Orthopedics 28(2):143-147
19. Bevan JS, Newell-Price J, Wass JA, Atkin SL, Bouloux PM, Chapman J, Davis JR, Howlett TA, Randeva HS, Stewart PM, Viswanath A (2008) Home administration of lanreotide Autogel by patients with acromegaly, or their partners, is safe and effective. Clin Endocrinol (Oxf) 68(3):343-349